Bispecific antibodies come to the aid of cancer immunotherapy

Three collaborative studies published by the groups of Vogelstein, Gabelli, and Zhou report the development of specially designed bispecific antibodies that may help in overcoming the limitations of current immunotherapies. The bispecific antibodies have been designed to couple cells harboring HLA‐p...

Descripción completa

Detalles Bibliográficos
Autores principales: Amelio, Ivano, Melino, Gerry, Levine, Arnold J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253090/
https://www.ncbi.nlm.nih.gov/pubmed/33942515
http://dx.doi.org/10.1002/1878-0261.12977
_version_ 1783717438298259456
author Amelio, Ivano
Melino, Gerry
Levine, Arnold J.
author_facet Amelio, Ivano
Melino, Gerry
Levine, Arnold J.
author_sort Amelio, Ivano
collection PubMed
description Three collaborative studies published by the groups of Vogelstein, Gabelli, and Zhou report the development of specially designed bispecific antibodies that may help in overcoming the limitations of current immunotherapies. The bispecific antibodies have been designed to couple cells harboring HLA‐presented tumor‐specific antigens from Tp53 mutant or Ras mutant with CD4 and CD8 T cells, thus facilitating immune‐mediated clearance of the cancer cells.[Image: see text]
format Online
Article
Text
id pubmed-8253090
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-82530902021-07-13 Bispecific antibodies come to the aid of cancer immunotherapy Amelio, Ivano Melino, Gerry Levine, Arnold J. Mol Oncol Commentary Three collaborative studies published by the groups of Vogelstein, Gabelli, and Zhou report the development of specially designed bispecific antibodies that may help in overcoming the limitations of current immunotherapies. The bispecific antibodies have been designed to couple cells harboring HLA‐presented tumor‐specific antigens from Tp53 mutant or Ras mutant with CD4 and CD8 T cells, thus facilitating immune‐mediated clearance of the cancer cells.[Image: see text] John Wiley and Sons Inc. 2021-05-14 2021-07 /pmc/articles/PMC8253090/ /pubmed/33942515 http://dx.doi.org/10.1002/1878-0261.12977 Text en © 2021 The Authors. Molecular Oncology published by John Wiley & Sons Ltd on behalf of Federation of European Biochemical Societies. https://creativecommons.org/licenses/by/4.0/This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
spellingShingle Commentary
Amelio, Ivano
Melino, Gerry
Levine, Arnold J.
Bispecific antibodies come to the aid of cancer immunotherapy
title Bispecific antibodies come to the aid of cancer immunotherapy
title_full Bispecific antibodies come to the aid of cancer immunotherapy
title_fullStr Bispecific antibodies come to the aid of cancer immunotherapy
title_full_unstemmed Bispecific antibodies come to the aid of cancer immunotherapy
title_short Bispecific antibodies come to the aid of cancer immunotherapy
title_sort bispecific antibodies come to the aid of cancer immunotherapy
topic Commentary
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8253090/
https://www.ncbi.nlm.nih.gov/pubmed/33942515
http://dx.doi.org/10.1002/1878-0261.12977
work_keys_str_mv AT amelioivano bispecificantibodiescometotheaidofcancerimmunotherapy
AT melinogerry bispecificantibodiescometotheaidofcancerimmunotherapy
AT levinearnoldj bispecificantibodiescometotheaidofcancerimmunotherapy

Ejemplares similares